EUVIMEDEUVIMED entdecken
Open Access

Bleeding in patients with lung adenocarcinoma receiving concurrent administration of anticoagulation and vascular endothelial growth factor or epidermal growth factor receptor inhibitors

Thomas F Fusillo, Avi Leader, Simon Mantha, Helen Ajufo, Andriy Derkach, Adam Schoenfeld, Rohan Singh, Peter Kaplinsky, Jeffrey I Zwicker

Journal of Thrombosis and Haemostasis · 2026

DOI: 10.1016/j.jtha.2026.05.028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026. Verfasst von Thomas F Fusillo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Morningside/West, New York, New York, USA; Department of Medici…. Hauptthemen laut MEDLINE: Lung Neoplasms, ErbB Receptors, Hemorrhage, Anticoagulants. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health, National Institutes of Health National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Vascular endothelial growth factor (VEGF) inhibitors and epidermal growth factor receptor (EGFR) inhibitors are used to treat various cancers, including lung adenocarcinoma, but their associated bleeding risks when combined with anticoagulation therapy are largely unknown. OBJECTIVES: We sought to determine whether coadministration of VEGF inhibitors or EGFR inhibitors with anticoagulation therapy in patients with lung adenocarcinoma is associated with higher clinically relevant bleeding risks than in patients receiving anticoagulation therapy with systemic therapy alone. PATIENTS/METHODS: We conducted a single-center retrospective cohort study of patients treated for lung adenocarcinoma with therapeutic anticoagulation and concurrent systemic cancer therapy alone, VEGF inhibitors ± systemic therapy, or EGFR inhibitors ± systemic therapy. The index was the first day of concomitant anticoagulation and cancer treatment. Patients were followed for 12 months, and major bleeding and clinically relevant nonmajor bleeding (CRNMB) outcomes were collected using an internally validated natural language processing tool. RESULTS: A total of 464 patients were included, comprising 156 (34%) systemic therapy alone, 208 (45%) EGFR inhibitors, and 100 (22%) VEGF inhibitors. The 12-month cumulative incidence of major bleeding was statistically similar in the 3 cohorts: VEGF inhibitor (10%; 95% CI, 3.4%-22%), EGFR inhibitor (11%; 95% CI, 6.5%-17%), and systemic therapy cohort (9.3%; 95% CI, 4.1%-17%). We observed statistically similar risks of CRNMB with VEGF inhibitors (hazard ratio, 1.51; 95% CI, 0.71-3.20) and EGFR inhibitors (hazard ratio, 1.35; 95% CI, 0.65-2.80) versus systemic therapy alone. Epistaxis was the most common site, accounting for 25% of clinically relevant events. CONCLUSIONS: Concomitant administration of VEGF inhibitors and anticoagulation therapy was not associated with statistically significant increased risks of major bleeding or CRNMB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsErbB ReceptorsHemorrhageAnticoagulantsVascular Endothelial Growth Factor AAdenocarcinomaProtein Kinase InhibitorsHumansMaleFemaleRetrospective StudiesAdenocarcinoma of LungAgedRisk FactorsMiddle AgedTreatment OutcomeTime FactorsAged, 80 and over

Stichwörter der Autor:innen

adenocarcinoma of lunganticoagulantschemotherapyhemorrhagevascular endothelial growth factors

Substanzen

ErbB ReceptorsAnticoagulantsVascular Endothelial Growth Factor AProtein Kinase InhibitorsEGFR protein, humanVEGFA protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Morningside/West, New York, New York, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
  • Hematology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Division of Hematology, Department of Medicine, Washington University, St. Louis, Missouri, USA.
  • Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Förderung

  • NCI NIH HHS
  • National Institutes of Health
  • National Institutes of Health National Cancer Institute

Zitieren

APA

Fusillo, T. F., Leader, A., Mantha, S., Ajufo, H., Derkach, A., Schoenfeld, A., Singh, R., Kaplinsky, P., & Zwicker, J. I. (2026). Bleeding in patients with lung adenocarcinoma receiving concurrent administration of anticoagulation and vascular endothelial growth factor or epidermal growth factor receptor inhibitors. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2026.05.028

Vancouver

Fusillo TF, Leader A, Mantha S, Ajufo H, Derkach A, Schoenfeld A, et al. Bleeding in patients with lung adenocarcinoma receiving concurrent administration of anticoagulation and vascular endothelial growth factor or epidermal growth factor receptor inhibitors. Journal of Thrombosis and Haemostasis. 2026. doi:10.1016/j.jtha.2026.05.028

BibTeX
@article{Fusillo2026,
  author = {Fusillo, Thomas F and Leader, Avi and Mantha, Simon and Ajufo, Helen and Derkach, Andriy and Schoenfeld, Adam and Singh, Rohan and Kaplinsky, Peter and Zwicker, Jeffrey I},
  title = {Bleeding in patients with lung adenocarcinoma receiving concurrent administration of anticoagulation and vascular endothelial growth factor or epidermal growth factor receptor inhibitors},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2026},
  doi = {10.1016/j.jtha.2026.05.028}
}
Kostenlos starten →